Sublingual immunotherapy of house dust mite respiratory allergy in China
Main Article Content
Keywords
Sublingual immunotherapy, Allergic rhinitis, Asthma, House dust mite, China
Abstract
Sublingual immunotherapy (SLIT) has been widely used for the treatment of allergic respiratory diseases, but many problems remain unsolved. Currently available data suggest that SLIT is very effective in children and adults with IgE-mediated respiratory diseases. Most allergists in China generally believe that SLIT is suitable for allergic rhinitis and asthma due to its safety and tolerability. SLIT for three years is suitable for patients to acquire stable therapeutic effects, and the efficacy of single-allergen SLIT for polysensitized patients has also been confirmed. Nevertheless, there are still several factors restricting its application in China, such as the uncertainty of its long-term effects and the prevention of new sensitizations onset, the risk of asthma attacks, the low public awareness of SLIT and poor compliance by patients. This is a narrative review of current evidence on SLIT coming from China.
References
1. Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, et al. Eaaci guidelines on allergen immunotherapy: prevention of allergy. Pediatr Aller Immunol. 2017.
2. Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71:1170-80.
3. Li F, Zhou Y, Li S, Jiang F, Jin X, Yan C, et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health. 2011;11:437.
4. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2017.
5. Pajno GB, Bernardini R, Peroni D, Arasi S4, Martelli A, Landi M, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatrics. 2017;43:13.
6. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Aller Clin Immunol. 2015;136:556-68.
7. Pelaia C, Vatrella A, Lombardo N, Terracciano R, Navalesi P, Savino R, et al. Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children. Expert Opin Biol Ther. 2017:1-8.
8. Wang DH, Chen L, Cheng L, Li KN, Yuan H, Lu JH, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013;123:1334-40.
9. Tian M, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4+CD25+ regulatory T cells in peripheral blood of children with allergic asthma. Int Forum Allergy Rhinol. 2014;4:371-5.
10. Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M, et al. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides farinae drops. Zhonghua Er Ke Za Zhi. 2007;45:736-41 (Article in Chinese with English abstract, and indexed for MEDLINE/PubMed).
11. Wang C, Wang K, Liu S, Qin X, Chen K, Zhang T. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. Int J Pediatr Otorhinolaryngol. 2016;81: 15-20.
12. Shao J, Cui YX, Zheng YF, Peng HF, Zheng ZL, Chen JY, et al. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol. 2014;28:131-9.
13. Lin ZB, Zhou LF, Xia WT, Xia W, Chen D, Xu R, et al. Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2013;77:1345-9.
14. Li P, Li Q, Huang ZH, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol. 2014;4:796-801.
15. Yin GQ, Jiang WH, Wu PQ, He CH, Chen RS, Deng L. Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. Eur Rev Med Pharmacol Sci. 2016;20:4348-53.
16. Wang Z, Li W, Chen H, Zhang W. Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma. J Huazhong Univ Sci Technolog Med Sci. 2011;31:376-8.
17. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
18. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3-18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Aller Asthma Immunol. 2006;97:141-8.
19. Lin X, Lin H, Wei X, Huang Q. The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis. Aller Immunopathol (Madr). 2017;45:457-62.
20. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Aller Clin Immunol. 2012;129:929-34.
21. Li J, Sun B, Huang Y, Lin X, Zhao D, Tan G, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009;64: 1083-92.
22. Lind P, Hansen OC, Horn N. The binding of mouse hybridoma and human IgE antibodies to the major fecal allergen. Der p I, of Dermatophagoides pteronyssinus. Relative binding site location and species specificity studied by solid-phase inhibition assays with radiolabeled antigen. J Immunol. 1988;140:4256-62.
23. von Hertzen LC, Savolainen J, Hannuksela M, Klaukka T, Lauerma A, Mäkelä MJ, et al. Scientific rationale for the Finnish Allergy Programme 2008---2018: emphasis on prevention and endorsing tolerance. Allergy. 2009;64:678-701.
24. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Aller. 2003;33:206-10.
25. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Aller Clin Immunol. 2010;126:969-75.
26. Lin Z, Liu Q, Li T, Li T, Chen D, Chen D, et al. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. Int Forum Allergy Rhinol. 2016;6:82-7.
27. Meng Q, Liu X, Li P, He L, Xie J, Gao X, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. Int Forum Allergy Rhinol. 2016;6:862-70.
28. Zhong C, Yang W, Li Y, Zou L, Deng Z, Liu M, et al. Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma. Irish J Med Sci (1971-). 2017:1-6.
29. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Aller Clin Immunol. 2006;117:1021-35.
30. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35:560-4.
31. Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol. 2004;113:1219-20.
32. Wang T, Li Y, Wang F, Zhou C. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. Int Forum Allergy Rhinol. 2017;7:389-92.
33. Rhee CS. Current specific immunotherapy for allergic rhinitis: perspectives from otorhinolaryngologists. Allergy Asthma Immunol Res. 2014;6:273-5.
34. Zhou H, Tao QL, Wei JM, Xu G, Cheng L. Trends in specific immunotherapy for allergic rhinitis: a survey of Chinese ENT specialists. Allergy Asthma Immunol Res. 2014;6:296-303.
35. Cheng L. Clinical use and several problems of sublingual immunotherapy in China. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;50:617---8 (Article in Chinese, and indexed for MEDLINE/PubMed).
36. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854-67.
2. Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71:1170-80.
3. Li F, Zhou Y, Li S, Jiang F, Jin X, Yan C, et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health. 2011;11:437.
4. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2017.
5. Pajno GB, Bernardini R, Peroni D, Arasi S4, Martelli A, Landi M, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatrics. 2017;43:13.
6. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Aller Clin Immunol. 2015;136:556-68.
7. Pelaia C, Vatrella A, Lombardo N, Terracciano R, Navalesi P, Savino R, et al. Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children. Expert Opin Biol Ther. 2017:1-8.
8. Wang DH, Chen L, Cheng L, Li KN, Yuan H, Lu JH, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013;123:1334-40.
9. Tian M, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4+CD25+ regulatory T cells in peripheral blood of children with allergic asthma. Int Forum Allergy Rhinol. 2014;4:371-5.
10. Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M, et al. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides farinae drops. Zhonghua Er Ke Za Zhi. 2007;45:736-41 (Article in Chinese with English abstract, and indexed for MEDLINE/PubMed).
11. Wang C, Wang K, Liu S, Qin X, Chen K, Zhang T. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. Int J Pediatr Otorhinolaryngol. 2016;81: 15-20.
12. Shao J, Cui YX, Zheng YF, Peng HF, Zheng ZL, Chen JY, et al. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol. 2014;28:131-9.
13. Lin ZB, Zhou LF, Xia WT, Xia W, Chen D, Xu R, et al. Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2013;77:1345-9.
14. Li P, Li Q, Huang ZH, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol. 2014;4:796-801.
15. Yin GQ, Jiang WH, Wu PQ, He CH, Chen RS, Deng L. Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. Eur Rev Med Pharmacol Sci. 2016;20:4348-53.
16. Wang Z, Li W, Chen H, Zhang W. Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma. J Huazhong Univ Sci Technolog Med Sci. 2011;31:376-8.
17. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
18. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3-18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Aller Asthma Immunol. 2006;97:141-8.
19. Lin X, Lin H, Wei X, Huang Q. The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis. Aller Immunopathol (Madr). 2017;45:457-62.
20. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Aller Clin Immunol. 2012;129:929-34.
21. Li J, Sun B, Huang Y, Lin X, Zhao D, Tan G, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009;64: 1083-92.
22. Lind P, Hansen OC, Horn N. The binding of mouse hybridoma and human IgE antibodies to the major fecal allergen. Der p I, of Dermatophagoides pteronyssinus. Relative binding site location and species specificity studied by solid-phase inhibition assays with radiolabeled antigen. J Immunol. 1988;140:4256-62.
23. von Hertzen LC, Savolainen J, Hannuksela M, Klaukka T, Lauerma A, Mäkelä MJ, et al. Scientific rationale for the Finnish Allergy Programme 2008---2018: emphasis on prevention and endorsing tolerance. Allergy. 2009;64:678-701.
24. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Aller. 2003;33:206-10.
25. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Aller Clin Immunol. 2010;126:969-75.
26. Lin Z, Liu Q, Li T, Li T, Chen D, Chen D, et al. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. Int Forum Allergy Rhinol. 2016;6:82-7.
27. Meng Q, Liu X, Li P, He L, Xie J, Gao X, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. Int Forum Allergy Rhinol. 2016;6:862-70.
28. Zhong C, Yang W, Li Y, Zou L, Deng Z, Liu M, et al. Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma. Irish J Med Sci (1971-). 2017:1-6.
29. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Aller Clin Immunol. 2006;117:1021-35.
30. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35:560-4.
31. Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol. 2004;113:1219-20.
32. Wang T, Li Y, Wang F, Zhou C. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. Int Forum Allergy Rhinol. 2017;7:389-92.
33. Rhee CS. Current specific immunotherapy for allergic rhinitis: perspectives from otorhinolaryngologists. Allergy Asthma Immunol Res. 2014;6:273-5.
34. Zhou H, Tao QL, Wei JM, Xu G, Cheng L. Trends in specific immunotherapy for allergic rhinitis: a survey of Chinese ENT specialists. Allergy Asthma Immunol Res. 2014;6:296-303.
35. Cheng L. Clinical use and several problems of sublingual immunotherapy in China. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;50:617---8 (Article in Chinese, and indexed for MEDLINE/PubMed).
36. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854-67.
Article Sidebar
Published
Feb 15, 2019
Article Details
How to Cite
Cheng, L., & Zhou, W.-C. (2019). Sublingual immunotherapy of house dust mite respiratory allergy in China. Allergologia Et Immunopathologia, 47(1), 85-89. https://all-imm.com/index.php/aei/article/view/347
Issue
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Cheng, L., & Zhou, W.-C. (2019). Sublingual immunotherapy of house dust mite respiratory allergy in China. Allergologia Et Immunopathologia, 47(1), 85-89. https://all-imm.com/index.php/aei/article/view/347